Aurora, a Phase III global trial presented by the National Kidney Foundation (NKF), has revealed a possible drug for the treatment of lupus kidney disease.

The double-blind, placebo-controlled study was designed to evaluate experimental immunosuppressant drug Voclosporin (VCS), which is being developed by Aurinia Pharmaceuticals as a treatment for patients with lupus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Voclosporin is a novel high potency calcineurin inhibitor (CNI) with a favourable metabolic profile and a consistent predictable dose response. It potentially eliminates the need for therapeutic drug monitoring.

The Phase III Aurora trial enrolled 357 patients with active lupus nephritis (LN) to evaluate the efficacy and safety of VCS (23.7mg BID) versus placebo in combination with mycophenolate (MMF, 2 g/day) and rapidly tapered low dose oral steroids.

The study met its primary endpoint of renel response (RR) rates of 40.8% for voclosporin versus 22.5% for the control. All pre-specified hierarchical secondary endpoints also achieved statistical significance in favour of voclosporin.

These results suggest that the addition of VCS to MMF and low-dose steroids in active LN patients results in statistically superior and faster renal response rates versus standard of care.

Lead investigator Keisha Gibson said: “We are pleased to report that the patients who received voclosporin were 2.65 times more likely to meet the criteria for response based on proteinuria and eGFR.”

No differences in the safety profile between the voclosporin and standard care groups were reported in the study.

Aurinia is planning to file an application with the FDA for the approval of the drug.

Approximately 37 million adults are estimated to have chronic kidney disease in the US, while one in three adults are at risk for chronic kidney disease.